Biocompatible Hydrogel Polymer Formulations for the Controlled Delivery of Biomolecules

A method of delivering an antibody to a subject, the method comprising administering an in vivo gelling pharmaceutical pre-formulation, comprising:

• (a) one or more multi-ARM nucleophilic PEG monomers, wherein the multi-ARM PEG nucleophilic monomers comprise a polyol core, wherein the polyol core is selected from the group consisting of
• wherein the polyol core is substituted with 3-8 R-groups, wherein R is:
• wherein n is 1-200;
• (b) one or more multi-ARM nucleophilic PEG monomers, wherein the multi-ARM PEG nucleophilic monomers comprise a polyol core, wherein the polyol core is selected from the group consisting of
• wherein the polyol core is substituted with 3-8 R-groups, wherein R is:
• wherein n is 1-200;
• (c) one or more multi-ARM-PEG electrophilic monomers having more than two electrophilic arms, wherein each electrophilic arm comprises a PEG chain and terminates in an electrophilic group;
• (d) an aqueous buffer in the pH range of about 5.0 to about 9.5;
• and
• (e) at least one pharmaceutically active biomolecule that is a monoclonal antibody;
• wherein the in vivo gelling pharmaceutical pre-formulation at least in part polymerizes and/or gels at a target site of a human body to form a biocompatible hydrogel polymer,
• wherein the molecular weight of the multi-ARM PEG nucleophilic monomers and/or the multi-ARM PEG electrophilic monomers is about 500 to about 40000.